Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations

Yohann Loriot, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the first results from the NORSE study, a Phase II trial evaluating erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and FGFR alterations. Erdafitinib and cetrelimab showed clinially meaningful responses in cis-ineligible evaluable patients with first-line metastatic urothelial cancer and FGFR alterations. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Loriot is the investigator for JNJ-sponsored trials; received an institutional grant from JNJ; received fees for lectures from JNJ.